HUD is issuing the Preservation and Reinvestment Initiative for Community Enhancement (PRICE) competition NOFO to preserve long-term housing affordability for residents of manufactured housing or an MHC, to redevelop MHCs, and to primarily benefit low- and moderate-income (LMI) residents. Congress appropriated in FY2025 these competitive grants to preserve and revitalize manufactured housing and eligible manufactured housing communities and directed HUD to undertake a competition under title I of the Housing and Community Development Act of 1974, as amended (42 U.S.C. 5301 et seq.).
Community and Economic DevelopmentHousingPreservation
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 21, 2026
Summary: The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Discovery Award supports innovative, untested, groundbreaking research that provides new insights and explores early concepts in combat-relevant burn care that provide the foundation for future translational and/or clinical research. The proposed project may be exploratory, hypothesis-driven, or hypothesis-generating research, but must be novel and must be based on a strong scientific rationale and a well-developed study design.
Distinctive Features: The focus of this award mechanism is innovation. Proposed research should lay the groundwork for future avenues of scientific investigation or product development in the area of combat-relevant burn care. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for groundbreaking future research projects.
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 21, 2026
Summary: The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Technology/Therapeutic Development Award (TTDA) is a burn-focused, product-driven award mechanism intended to provide support for the translation of promising preclinical findings into burn products for clinical application in an austere, resource-limited, distributed operational environment.
Distinctive Features: The technology or therapeutic product(s) to be developed must be product-oriented (e.g., medical device, drug, or clinical practice guidelines involving a therapeutic or technology). The product(s) to be developed may be tangible or knowledge supporting the development of a tangible product and must address one or more of the FY26 MBRP TTDA focus areas. Knowledge products are allowable, provided that the knowledge is applicable to a technology or therapeutic under development. (A “knowledge product” is a non-tangible, non-materiel product that results from research with the potential to improve individual or public health.)
· New for FY26: The FY26 MBRP TTDA offers a Mentorship Option at a higher funding level to support a synergistic relationship between an experienced researcher (Mentor) and one to two junior researchers (Mentees). The dual purpose of this award is to fund a primary research study addressing a critical gap in combat burn care while simultaneously fostering the development of the next generation of military burn research leaders.
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 21, 2026
Summary: Despite significant research investment in combat-relevant burn care, a disparity exists between newly discovered knowledge in burn care and its implementation into clinical practice across the distributed operational battlespace. The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Patient-Centered Research Award (PCRA) seeks to bridge the gap between research, practice, and policy by developing a knowledge base that provides clinically useful findings about how interventions, clinical practices, guidelines, tools, and policies can be deployed to burn patients in an austere, resource-limited, military operational environment.
Distinctive Features:
· This award mechanism must support clinical research or clinical trials but cannot support preclinical or animal research . Applications may propose prospective or retrospective research involving human subjects or human subject data.
· New for FY26: The FY26 PCRA offers a Mentorship Option at a higher funding level to support a synergistic relationship between an experienced researcher (Mentor) and one to two junior researchers (Mentees). The dual purpose of this award is to fund a primary research study addressing a critical gap in combat burn care while simultaneously fostering the development of the next generation of military burn research leaders.
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 22, 2026
Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Distinctive Features:
Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest.
Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical Trial Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in autism clinical trial research.
FY26 Clinical Trial Award submissions are required to include community collaborations to optimize research impact. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research. Applications to the FY26 ARP Clinical Trial Award are expected to name at least one community partner (e.g., Autistic individual or caregiver, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings (see Attachment 12, Community Collaboration Plan).
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 22, 2026
Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.
Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.
Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 22, 2026
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Idea Development Award (IDA) is to support conceptually innovative research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or the quality of life. Applications should propose research that is conceptually innovative, introduces a new concept or question, challenges existing paradigms, approaches issues from a new perspective, or exhibits other uniquely creative qualities; and should not merely be a next logical step or an incremental advance on published data or ongoing research.
Distinctive Features: A Career Development Option is available to eligible early-career investigators who propose to conduct impactful mechanism-relevant research under the mentorship of an experienced tick-borne disease researcher(s). Applications submitted under the IDA – Career Development Option (IDA-CDO) will be reviewed using separate, career development-specific evaluation criteria by a separate, dedicated peer review panel; and are subject to a lower cost limit than those submitted under the standard IDA.
https://cdmrp.health.mil/pubs/press/2026/tbdrppreann
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 22, 2026
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.
https://cdmrp.health.mil/pubs/press/2026/tbdrppreann
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 22, 2026
Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Clinical Research Award (CRA) supports clinical research that evaluates disease-specific factors and interventions. Research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Research addressing any and all types of arthritis is encouraged.
Applications must address one of two FY26 ATRP CRA Focus Areas: Prevention and Early Diagnosis, or Treatment and Mitigation of Disease Progression/Burden.
Distinctive Features: The FY26 ATRP CRA offers funding for two research levels. It is the responsibility of the applicant to select the level that aligns with the scope of the proposed research.
• Research Level 1: Applications proposing clinical research or early-phase/pilot clinical trials, to include new or emerging research that is not ready for a full-scale randomized controlled clinical trial.
• Research Level 2: Applications proposing a full-scale clinical trial.
Applications should include a community collaborator (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. The ATRP encourages a community collaborator for Research Level 1 applications and requires a community collaborator for Research Level 2 applications.
Preliminary and/or published data are required.
Defense Health Agency Contracting Activity - DHACA
Award
Varies
Deadline
Oct 22, 2026
Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for Autistic individuals. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.
Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Idea Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in autism.
Partnering Principal Investigator (PI) Option: The Partnering PI Option is structured so that two investigators, each of whom will be designated as a PI, will work synergistically on a single project. The results of this partnering project should significantly advance the research beyond what would be possible through individual efforts.